Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I-II study.

Morganti AG, Mignogna S, Caravatta L, Deodato F, Macchia G, Plantamura NM, Massaccesi M, Picardi V, Cilla S, Valentini V.

J Chemother. 2014 Dec;26(6):353-8. doi: 10.1179/1973947813Y.0000000163. Epub 2014 Jan 27.

PMID:
24621170
2.

Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study.

Morganti AG, Cellini F, Mignogna S, Padula GD, Caravatta L, Deodato F, Picardi V, Macchia G, Cilla S, Buwenge M, Di Lullo L, Gambacorta MA, Balducci M, Mattiucci GC, Autorino R, Valentini V.

Future Oncol. 2016 Mar;12(6):779-87. doi: 10.2217/fon.15.350. Epub 2016 Feb 1.

PMID:
26829128
3.

Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.

Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, Pericay C, Pastorelli D, Tarazi J, Rosbrook B, Bloom J, Ricart AD, Kim S, Sobrero AF.

Clin Colorectal Cancer. 2013 Dec;12(4):239-47. doi: 10.1016/j.clcc.2013.09.001.

PMID:
24188685
4.

Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.

Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, Mainwaring P, Langer B, Young S; AVIRI Trial investigators.

Oncology. 2009;77(2):113-9. doi: 10.1159/000229787. Epub 2009 Jul 23. Erratum in: Oncology. 2009;77(2):following 119. Chiara, Silvia [corrected to Chiara, Silvana]. Oncology. 2009;77(3-4):256.

5.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S.

Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31.

PMID:
25088940
6.

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.

Kochi M, Akiyama Y, Aoki T, Hagiwara K, Takahashi T, Hironaka K, Teranishi F, Osuka F, Takeuchi M, Fujii M, Nakajima T.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1097-102. doi: 10.1007/s00280-013-2292-9. Epub 2013 Sep 22.

PMID:
24057041
7.

Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment.

Odabas H, Ozdemir N, Isik M, Abali H, Oksuzoglu B, Kos T, Civelek B, Babacan AN, Dogan U, Zengin N.

J BUON. 2011 Jul-Sep;16(3):460-3.

PMID:
22006750
8.

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A.

N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.

9.

[Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].

Abe H, Mafune K, Minamimura K, Abe M, Umemura A, Hirata T.

Gan To Kagaku Ryoho. 2013 May;40(5):601-4. Japanese.

PMID:
23863581
10.

A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.

López R, Salgado M, Reboredo M, Grande C, Méndez JC, Jorge M, Romero C, Quintero G, de la Cámara J, Candamio S.

Br J Cancer. 2010 Nov 9;103(10):1536-41. doi: 10.1038/sj.bjc.6605938. Epub 2010 Oct 12.

11.

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.

Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P.

BMC Cancer. 2009 Sep 28;9:347. doi: 10.1186/1471-2407-9-347.

12.

Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.

Kocakova I, Melichar B, Kocak I, Bortlicek Z, Büchler T, Dusek L, Petruzelka L, Kohoutek M, Prausová J, Finek J, Mohelnikova-Duchonova B, Vyzula R.

Anticancer Res. 2015 Jun;35(6):3455-61.

PMID:
26026110
13.

[The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older].

Chika N, Ishibashi K, Okada N, Tajima Y, Kumamoto K, Kumagai Y, Baba H, Haga N, Sano M, Ishida H.

Gan To Kagaku Ryoho. 2014 Jul;41(7):857-62. Japanese.

PMID:
25131872
14.

Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.

Lee EK, Revil C, Ngoh CA, Lister J, Kwon JM, Park MH, Park SJ, Park YS, Shin SJ, Lee MA, Lee NS, Zang DY, Bae EJ, Kang MJ.

Clin Ther. 2012 Jun;34(6):1408-19. doi: 10.1016/j.clinthera.2012.05.001. Epub 2012 May 31.

PMID:
22657254
15.

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.

Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T, Gayet B, Hebbar M, Goebel FM, Tournigand C, Parc R, de Gramont A.

J Clin Oncol. 2005 Jan 20;23(3):502-9.

PMID:
15659495
16.

Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.

Nasti G, Piccirillo MC, Izzo F, Ottaiano A, Albino V, Delrio P, Romano C, Giordano P, Lastoria S, Caracò C, de Lutio di Castelguidone E, Palaia R, Daniele G, Aloj L, Romano G, Iaffaioli RV.

Br J Cancer. 2013 Apr 30;108(8):1566-70. doi: 10.1038/bjc.2013.140. Epub 2013 Apr 4.

18.
19.

The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.

Budai B, Nagy T, Láng I, Hitre E.

Angiogenesis. 2013 Jan;16(1):113-21. doi: 10.1007/s10456-012-9303-z. Epub 2012 Sep 6.

PMID:
22956187
20.

FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.

Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Maspero F, Sauta MG, Beretta GD, Barni S.

Clin Colorectal Cancer. 2013 Sep;12(3):145-51. doi: 10.1016/j.clcc.2013.04.006. Epub 2013 Jun 10. Review.

PMID:
23763824

Supplemental Content

Support Center